WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the sale of ILUVIEN® for diabetic macular edema (DME) has begun in Portugal .

Now Approved in 14 Countries Worldwide WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the Dutch Inspectie voor de Gezondheidszorg (IGZ) has granted

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton , president and chief executive officer, will present at the upcoming LD Micro

Now Approved in 13 Countries Worldwide WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the Irish Health Products Regulatory Authority (HPRA) has

Now Approved in 12 Countries Worldwide WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the Belgian Federal Agency for Medicines and Health Products

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its first quarter ended September 30, 2014 .

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its financial results for the first quarter of fiscal year 2015 will be released before the market

Planned Operations Funded into 2017 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV, ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that it has received the $25 million milestone payment under its

pSivida earns $25 million milestone WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved ILUVIEN®

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that it has elected James J. Barry, Ph.D. to its Board of Directors. Dr.

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its fourth quarter and fiscal year ended June 30, 2014 .

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its financial results for the fourth quarter and fiscal year 2014 will be released after the market

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Swedish Medical Products Agency granted marketing authorization to ILUVIEN® for the treatment of

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Danish Health and Medicines Authority granted marketing authorization to ILUVIEN® for the

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that ILUVIEN® has been has granted marketing authorization in Norway for the treatment of vision

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the regulatory process for marketing authorizations in Belgium , the Czech Republic , Denmark ,

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to

Now Plans to Seek US approval of Medidur for Posterior Uveitis Based on One Phase III Trial WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that the Company presented the first peer-reviewed preclinical data demonstrating the use of pSivida's Tethadur™

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its financial results for the third quarter of fiscal year 2014 will be released after the market